Treatments for fragile X syndrome: A closer look at the data
Open accessAbstract
Research into the determinants and developmental course of fragile X syndrome (FXS) has made remarkable progress over the last 25 years. However, treatments to ameliorate the symptoms of FXS have been less forthcoming. While there is optimism in the field that the pace of intervention research is quickening, there has been a bias toward psychopharmacological approaches to treatment. A closer look at the data from those investigations reveals a paucity of evidence that medications can improve intellectual and adaptive functioning in FXS, or decrease associated behavioral and/or emotional issues. Work in other related disorders (e.g., autism) has shown that dramatic improvements in intellectual and adaptive functioning, as well as behavioral and emotional problems, can occur if intensive behavioral treatment is begun early in the child's life. It is hoped that future research efforts will evaluate these intensive early intervention strategies in children with FXS, perhaps in combination with pharmacological approaches. © 2009 Wiley‐Liss, Inc. Dev Disabil Res Rev 2009;15:353–360.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Psychostimulants are the most often prescribed psychoactive medication to treat FXS.
“Psychostimulants are the most often prescribed psychoactive medication to treat FXS [730]”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [730]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 49 · Cited by 56
Research works printed but not linked: 2
- Hagerman RJ 2002b Medical follow-up and pharmacotherapy Hagerman RJ Hagerman PJ Fragile X syndrome: diagnosis, treatment, and research 3rd Baltimore The Johns Hopkins University Press 287 338
- Scharfenaker S O'Connor R Stackhouse T 2002 An integrated approach to intervention Hagerman RJ Hagerman PJ Fragile X syndrome: diagnosis, treatment, and research 3rd Baltimore The Johns Hopkins University Press 363 427
- Authors
- Hall, S. S.
- Affiliations
- Stanford University (US)
- Corresponding author
- Hall, Scott S.
- ORCID
- Hall, Scott S.
- Venue
- Developmental Disabilities Research Reviews
- Publisher
- Wiley
- Published
- 2009-01
- Volume
- 15
- Issue
- 4
- Pages
- 353-360
- ISSN
- 1940-5510 (ISSN-L)
- 1940-5529
- PMC
- PMC2898566
- OpenAlex
- W1969894817
- Cited by
- 56
- References
- 49
- Citations by year
- 2026: 1 · 2023: 1 · 2022: 2 · 2020: 8 · 2019: 6 · 2018: 2 · 2017: 2 · 2016: 3 · 2015: 5 · 2014: 7 · 2013: 4 · 2012: 6
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Developmental Disabilities Research Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Fragile X Foundation
- National Institutes of Health
- National Institute of Mental Health (K08MH081998)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Keywords
- fragile X syndrome, psychopharmacological interventions, intellectual functioning, adaptive behavior, behavioral problems, emotional problems, behavior therapy
- MeSH terms
- Acetylcarnitine, Adrenergic alpha-Agonists, Central Nervous System Stimulants, Behavior Therapy, Clonidine, Folic Acid, Fragile X Syndrome, Humans, Memantine, Dopamine Agonists, Fragile X Messenger Ribonucleoprotein 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
